Quest Diagnostics (DGX) Investor Day 2025 summary

Strategic direction and market outlook

• Targeting 4-5% annual revenue growth and 7-9% adjusted EPS growth beyond 2025, driven by advanced diagnostics, operational improvements, and above-market expansion in physician and health system segments.

• Expanding in high-growth areas such as consumer-initiated testing, life sciences, analytics, and advanced diagnostics, aiming for over 20% combined CAGR in these segments.

• Leveraging recent acquisitions, including eight completed in 2024, expected to generate approximately $1 billion in annualized revenue, and building strategic partnerships to access new markets.

• Committed to leveraging scale, EMR connectivity, and national reach to serve large physician groups and health systems, enhancing competitive advantage.

• Pursuing disciplined M&A, targeting regional labs, health system outreach, and capability-building assets, with strict accretion and ROIC criteria.

Innovation and business development

• Investing in five key clinical areas: oncology, cardiometabolic health, women's and reproductive health, brain health, and autoimmune disorders, with advanced diagnostics expected to reach $1.2 billion revenue by 2027.

• Launching proprietary and partnered tests, such as Haystack MRD for oncology, ADDETECT for Alzheimer's, and advanced cardiometabolic biomarkers, to address unmet clinical needs and drive double-digit growth.

• Expanding direct-to-consumer offerings and data analytics, with consumer testing growing over 40% last year and analytics serving pharma, health plans, and public health agencies.

• Collaborating with academic, industry, and technology partners to accelerate innovation and market access for new diagnostics.

• Investments in automation, AI, and digital solutions across the value chain to improve quality, productivity, and customer experience, including Project Nova to modernize order-to-cash processes.

Operational excellence and productivity

• Invigorate program and other initiatives target 3% annual productivity and cost savings through standardization, digitization, and AI-driven process improvements.

• Deploying modular automation, robotics, and digital cytology to address labor shortages, improve throughput, and enhance medical quality in labs.

• Project Nova aims to unify and upgrade IT systems, streamline processes, and enable enterprise-wide changes, with benefits ramping from 2027 and completion by 2032.

• Employee engagement and retention initiatives have reduced attrition by over five percentage points in two years, supporting operational stability.

• Achieving high customer satisfaction, with patient NPS of 74 and physician satisfaction at 86%, well above industry averages.